ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women

Recruiting now

Conditions studied: Menopause, Estrogen Deficiency

In brief

This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted adult women. Participants will receive the supplement for 12 weeks, and adherence will be assessed as the percentage of doses consumed and the proportion of participants achieving ≥80% adherence. Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include changes in muscle strength, body composition, quality of life, joint pain, and skin health.

Key facts

Study ID

NCT07580846

Run by

Margan Biotech

People needed

100

Starts

2026-03-20

Expected to finish

2026-10-01

Last updated by the study team

2026-05-12

Who can join

Age: 40 and older, up to 75. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Biological female sex.
• Age ≥40 years.
• Estrogen-depleted status, defined as at least one of the following:
• natural menopause, defined as amenorrhea for ≥12 consecutive months; surgically induced menopause; late perimenopause with elevated FSH according to clinical judgment.
• Absence of major comorbidities that would contraindicate use of the nutritional supplement or the recommended physical activity.
• No relevant changes in usual treatment during the previous 3 months.
• Ability to understand the study information and provide written informed consent.
• Willingness to take the nutritional supplement according to the study instructions.
• Willingness to follow general physical activity recommendations provided by the investigator.
• Willingness and ability to attend the planned visits and complete study assessments through Week 12.

You may not qualify if…

• Initiation or modification of treatment with GLP-1 receptor agonists within the previous 12 weeks.
• Presence of musculoskeletal or joint conditions that significantly limit the ability to perform regular physical activity or study-related functional assessments.
• Clinically relevant renal or hepatic disease.
• Current use of diuretics or potentially nephrotoxic medications.
• Known allergy or intolerance to any component of the nutritional supplement.
• Participation in another clinical study (nutritional, pharmacological, or interventional) within the previous 3 months.
• Any medical condition or social circumstance that, in the investigator's judgment, could interfere with study participation, adherence, or data validity.

Where it is running

• Clínica Palacios — Madrid, Madrid, Spain (enrolling)
• Menoclinica by Palacios — Madrid, Madrid, Spain (enrolling)
• Ginegetafe — Madrid, Madrid, Spain (enrolling)
• Clinica Palacios Málaga — Málaga, Málaga, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.